DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus

Recruiting

Conditions: Long-Term Organ Damage in Adult Patients With Active Systemic Lupus Erythematosus

First Posted Date: 2024-07-03

Last Posted Date: 2025-05-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 478

Registration Number: NCT06485674

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Phase 3

Recruiting

Conditions: Severe Asthma

Interventions: Combination Product: Tezepelumab
Combination Product: Budesonide/formoterol
Combination Product: Albuterol/budesonide (AIRSUPRA®)
Combination Product: Mannitol
Combination Product: Salbutamol

First Posted Date: 2024-06-25

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 300

Registration Number: NCT06473779

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Recruiting

Conditions: Severe Asthma

First Posted Date: 2024-06-25

Last Posted Date: 2025-05-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 5000

Registration Number: NCT06472310

Locations: 🇷🇺
Research Site, Yekaterinburg, Russian Federation

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

Phase 3

Recruiting

Conditions: Asthma

Interventions: Combination Product: Budesonide/Albuterol metered dose inhaler, MDI
Combination Product: Albuterol sulfate metered dose inhaler, MDI

First Posted Date: 2024-06-24

Last Posted Date: 2025-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 790

Registration Number: NCT06471257

Locations: 🇭🇰
Research Site, Hong Kong, Hong Kong

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: AZD5148
Drug: Placebo

First Posted Date: 2024-06-21

Last Posted Date: 2025-04-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 84

Registration Number: NCT06469151

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Phase 3

Recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Gemcitabine
Drug: Trastuzumab deruxtecan
Drug: Rilvegostomig
Drug: Cisplatin
Diagnostic Test: Agilent HercepTest™ mAb pharmDx
Drug: Durvalumab
Diagnostic Test: Ventana PD-L1 SP263 assay

First Posted Date: 2024-06-21

Last Posted Date: 2025-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 620

Registration Number: NCT06467357

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Recruiting

Conditions: ATTR
ATTR-CM
ATTR-Mixed
Transthyretin Amyloidosis
hATTR
ATTRv-PN

Interventions: Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting

First Posted Date: 2024-06-20

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 1600

Registration Number: NCT06465810

Locations: 🇬🇧
Research Site, London, United Kingdom

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

Phase 3

Active, not recruiting

Conditions: Severe Eosinophilic Asthma

Interventions: Drug: Benralizumab

First Posted Date: 2024-06-18

Last Posted Date: 2025-04-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 476

Registration Number: NCT06465485

Locations: 🇨🇳
Research Site, Zhengzhou, China

Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone

Withdrawn

Conditions: Prostatic Neoplasms

First Posted Date: 2024-06-13

Last Posted Date: 2025-03-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT06457854

Locations: 🇧🇷
Clínica AMO, Salvador, Bahia, Brazil
🇧🇷
Liga Norte Rio Grandense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
🇧🇷
Clínica Viver, Santa Maria, Rio Grande Do Sul, Brazil

and more 2 locations

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Phase 3

Recruiting

Conditions: Polymyositis, Dermatomyositis

Interventions: Combination Product: Anifrolumab (blinded)
Other: Placebo
Combination Product: Anifrolumab (unblinded, open label)

First Posted Date: 2024-06-12

Last Posted Date: 2025-04-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 240

Registration Number: NCT06455449

Locations: 🇻🇳
Research Site, Hue, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy